They showed that clopidogrel is an important therapeutic agent for both primary and secondary prevention of coronary heart disease and could be an alternative P2Y12 inhibitor especially for elderly patients with higher bleeding risk. This evidence concerns the gene P2RY12 and coronary artery disorder.